During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

In a new paper, a team from Yale and Fred Hutch has found autoantibody reactivity could predict cancer patients' response to ...

A landmark study has revealed that autoantibodies — immune proteins traditionally associated with autoimmune disease — may ...

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Researchers saw some cases where a patient’s own autoantibodies boosted likelihood of responding to checkpoint blockade.

A new study has revealed that autoantibodies—immune proteins traditionally associated with autoimmune disease—may profoundly ...

Radiation therapy, once thought of mainly as a local cancer treatment, is now showing power to awaken the immune system in surprising ways. Researchers discovered that combining radiation with ...

Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior ...

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

Patients with rheumatoid arthritis who undergo immune checkpoint inhibition for metastatic non-small cell lung cancer demonstrate similar overall survival as those without RA, according to data ...

The research highlights the potential of these immune proteins to enhance the effectiveness of checkpoint inhibitors in certain individuals.

From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...